Trade

Natco Pharma share price

Balanced risk
  • 33%Low risk
  • 33%Moderate risk
  • 33%Balanced risk
  • 33%High risk
  • 33%Extreme risk
  • ₹858.30(-3.77%)
    January 16, 2026 15:25:57 PM IST
    • NSE
    • BSE
  • Vol : 504.41 K (NSE + BSE)
    Last 20 day avg : 672.23 K

Natco Pharma is trading -3.77% lower at Rs 858.30 as compared to its last closing price. Natco Pharma has been trading in the price range of 892.00 & 864.10. Natco Pharma has given -1.23% in this year & -5.72% in the last 5 days. Natco Pharma has TTM P/E ratio 9.26 as compared to the sector P/E of 22.69.There are 10 analysts who have initiated coverage on Natco Pharma. There are 2 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 518.40 Crores in its last quarter.Listed peers of Natco Pharma include Torrent Pharmaceuticals (0.35%), Divi's Laboratories (-1.93%), Cipla (-2.52%).The Mutual Fund holding in Natco Pharma was at 2.20% in 30 Sep 2025. The MF holding has increased from the last quarter. The FII holding in Natco Pharma was at 14.09% in 30 Sep 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Jan 16, 2026, 10:54 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.76
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.04
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.56
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    0.08
    Indicates undervaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
864.10
Highest
892.00
52 week range
Lowest
660.05
Highest
1,340.45
Natco Pharma News
Natco Pharma Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Torrent Pharmaceuticals
Bullish
4,018.750.351,36,007.3067.3217.10.8317.62
Divi's Laboratories
Bearish
6,233.95-1.931,65,491.7978.6111.520.460.01
Cipla
Bearish
1,398.45-2.521,12,922.4622.953.870.870.81
Dr Reddy's Laboratories
Bearish
1,175.65-0.9198,110.3818.633.140.632.34
Sun Pharmaceutical Industries
Bearish
1,669.20-1.844,00,487.5636.245.770.920.50
Mutual Fund Ownership
View all
Tata Equity P/E Fund Regular Growth
3/5
  • Amount Invested (Cr.) 149.48
  • % of AUM 1.76
Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.35
  • % of AUM 1.42
Tata Nifty MidSmall Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.95
  • % of AUM 1.42
Axis Nifty Smallcap 50 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 5.86
  • % of AUM 1.20
Kotak Nifty Smallcap 50 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.57
  • % of AUM 1.20
Natco Pharma Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-14Quarterly Results & Interim Dividend
2025-08-12Quarterly Results & Interim Dividend
2025-05-28Audited Results
2025-02-12Quarterly Results & Interim Dividend
2024-11-12Quarterly Results & Interim Dividend
About the company Natco Pharma
  • IndustryBiotechnology & Drugs
  • ISININE987B01026
  • BSE Code524816
  • NSE CodeNATCOPHARM
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with a focus on research and development. It develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Its segments include Pharmaceuticals and Agro chemicals. The Pharmaceuticals segment is engaged in the manufacturing and selling of bulk drugs, finished dosage formulations. The Agro Chemicals segment focuses on the manufacturing and selling of agro chemicals. It is also engaged in developing, manufacturing and marketing finished dosage formulations (FDF), active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio consists of two categories of agrochemicals - pesticides and bioproducts. The key focus area is to fill the gaps in the portfolio through crop phenology analysis. It has manufacturing facilities in India which cater to both domestic and international markets.
  • Management Info
  • Venkaiah NannapaneniChairman of the Board, Managing Director, Executive Director
  • Rajeev NannapaneniChief Executive Officer, Vice Chairman of the Board, Executive Director
  • S. V. V. N. Appa RaoChief Financial Officer
  • Linga Rao DonthineniPresident - Technical Affairs, Executive Director
  • Amit ParekhExecutive Vice President - Finance and Accounts
  • Potluri PrasadExecutive Vice President - Corporate Engineering Services, Executive Director
  • Rajesh ChebiyamExecutive Vice President - Crop Health Sciences
  • N. Sadasiva RaoExecutive Vice President - Corporate Affairs, Legal & Secretarial, Estate Management
  • Lakshminarayana AreSenior Vice President - HR and OD
  • Imtiyaz BasadeSenior Vice President - RAD
Natco Pharma Share Price FAQs

Natco Pharma is trading at 858.30 as on Fri Jan 16 2026 09:55:57. This is -3.77% lower as compared to its previous closing price of 891.90.

The market capitalization of Natco Pharma is 15403.45 Cr as on Fri Jan 16 2026 09:55:57.

The average broker rating on Natco Pharma is Hold. The breakup of analyst rating is given below -

  • 2 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 3 analysts have given a hold rating
  • 2 analysts have given a sell rating
  • 2 analysts have given a strong sell rating

The 52 wk high for Natco Pharma is 1340.45 whereas the 52 wk low is 660.05

Natco Pharma can be analyzed on the following key metrics -

  • TTM P/E: 9.26
  • Sector P/E: 22.69
  • Dividend Yield: 0.56%
  • D/E ratio: 0.03

Natco Pharma reported a net profit of 1885.40 Cr in 2025.

The Mutual Fund Shareholding was 2.20% at the end of 30 Sep 2025.

Quick Links
EQUITY QUICK LINKS
Natco Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Natco Pharma share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.